Literature DB >> 3518822

A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.

J A Grebb, R C Shelton, E H Taylor, L B Bigelow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3518822     DOI： 10.1016/0006-3223(86)90132-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  8 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

Review 4.  Do calcium antagonists have a place in the treatment of mood disorders?

Authors:  C Höschl
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 5.  From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms.

Authors:  Zeeba D Kabir; Arlene Martínez-Rivera; Anjali M Rajadhyaksha
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

6.  Different effects of the calcium antagonists nimodipine and flunarizine on dopamine metabolism in the rat brain.

Authors:  F Fadda; G L Gessa; E Mosca; E Stefanini
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 7.  Calcium channel blockers for antipsychotic-induced tardive dyskinesia.

Authors:  Adib Essali; Karla Soares-Weiser; Hanna Bergman; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-03-26

8.  Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.

Authors:  T Lencz; A K Malhotra
Journal:  Mol Psychiatry       Date:  2015-04-14       Impact factor: 15.992
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.